<DOC>
	<DOC>NCT01209208</DOC>
	<brief_summary>The purpose of this study is to determine whether budesonide or mesalazine is more active in the treatment of lymphocytic colitis.</brief_summary>
	<brief_title>Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis</brief_title>
	<detailed_description />
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Colitis, Lymphocytic</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Signed informed consent Symptoms and signs of indication of lymphocytic colitis Infectious diarrhoea, Diarrhoea as a result of the presence of other symptomatic organic disease(s) of the gastrointestinal tract or endoscopichistological findings Celiac disease Pregnancy or breastfeeding, Participation in an other clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>